ReviewExploration of targeted anti-tumor therapy2026
Post-CDK4/6 inhibitor therapy in HR+/HER2- advanced breast cancer: expanding options and persisting uncertainties.
Anne-Murielle Hollinger et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.